100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Delivery Order 75N95018D00010-75N95020F00001
Award Date
9/29/20
Potential Completion Date
9/28/21
Potential Value
$27K
Overview
Contacts
Activity
2
Transactions
2
Subawards
Opportunity Stack
Similar Awards
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
A&G Pharmaceutical, Inc. SN6SWFABJXL1
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Not listed
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Columbia, MD 21045, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
75N95018D00010
Indefinite Delivery Contract
75N95018D00010-75N95020F00001
Delivery Order
Update #1
Update #2
GENERATING POLYCLONAL ANTIBODIES AGAINST PTH-IA, PERIOD OF PERFORMANCE 9/29/20 - 9/28/2021
Posted 9/29/20
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
Reagent Generation for Bioanalytical Method Development for Biologics
Added: Oct 13, 2017 10:13 am SUMMARY:This is a notice of a proposed contract action issued in accordance with FAR 5.203(a). The Government intends to issue RFP No. N01TR-18-2006, titled "Reagent Generation for Bioanalytical Method Development for Biologics," via FedBizOpps on or about October 31, 2017.REQUIREMENT AND TYPE OF SERVICE:The Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), conducts translational research in the area of human therapeutics development.The objective of this contract is to support the DPI drug development programs by generating reagents (e.g. polyclonal and monoclonal antibodies) that will be used in bioanalytical assay development to quantify concentrations of novel biologics and anti-drug antibodies(ADA) in biological samples (e.g. plasma, serum and tissue homogenate) collected from preclinical pharmacology, pharmacokinetic and toxicokinetic studies, as well as human pharmacokinetic studies in clinical trials.Under this contract, novel biologics include but are not limited to the following: mAbs, recombinant human proteins, Fc-fusion proteins, bio-functional proteins, PEGylated or other engineered peptides, protein fragments, antibody-drug conjugates (ADC), engineered human genes and carriers, in plasma/serum, tissue homogenates, and CSF.This RFP is a follow-up solicitation to NCATS RFP No. N01TR-17-2004, "CRO Support for NCATS Bioanalytical Method Development for Biologics," that was issued on January 26, 2017. In that RFP, the Statement of Work was divided into four technical areas: Technical Area 1: Reagent Generation; Technical Area 2: Bioanalytical Method Development for Novel Biologic Drugs; Technical Area 3: Bioanalysis of Novel Biologic Drugs in Biologic Matrices; and Technical Area 4: Determination of Anti-Drug Neutralizing Antibodies. To qualify for award, organizations had to demonstrate capabilities in at least one technical area. NCATS received no responses in Technical Area 1, Reagent Generation. Therefore, it is issuing a new RFP soliciting responses to the reagent generation requirement.RELEASE OF SOLICITATION:The Government intends to issue a Request for Proposals on or about October 31, 2017. Proposals will be due 45 calendar days following release of the RFP.The intended contract will be a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract under this solicitation.The ultimate goal of DPI and this planned project is to bring new drugs to market. To this end, the Government has issued a Determination of Exceptional Circumstances (DEC) to deviate from the Federal Acquisition Regulation clauses at 52.227-11 Patent Rights and 52.227-14 Rights in Data. The deviated language enables DPI contributors to retain control of their intellectual property, and will be included in the RFP and incorporated in any resultant contract. Prospective Offerors are advised that agreement to the terms of these FAR clauses deviations will be a condition for contract award.Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.This is a new requirement; therefore, no incumbent information is provided. The Government will select the proposal that is most advantageous to the Government in accordance with the basis of award included in the solicitation.The anticipated award date for this action is around July 1, 2018.ABOUT DPI AND NCATS:The Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline to predetermined milestones, at which point DPI will hand off the drug candidate to external partner(s) to bring the novel therapy to patients.In addition to developing new candidate drugs, DPI seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial pre-clinical stage of drug development. DPI's model is to operate as a full range small molecule and biologics drug development organization, moving drug candidates tough each phase of the pre-clinical drug development process until an IND is filed with the US Food and Drug Administration (FDA). For certain drug development programs, DPI will support its candidate's development up to human Phase IIB studies if such support will achieve DPI's mission.DPI conducts drug development as collaborations tough programs such as the Therapeutics for Rare and Neglected Diseases (TRND) and the Bridging Interventional Development Gaps (BrIDGs) programs. DPI drug development programs originate from academia, industry, non-profit foundations, or internally from NCATS and other NIH institutes, and its R&D operational strategy is to combine the capabilities of DPI in-house staff and DPI partners, who may be the drug originators. Each drug program operates in a multi-disciplinary, multi-partnership matrix team environment, and a DPI program officer (PO) is responsible for the overall planning, execution, and reporting of the program.Contract research organizations (CROs) and contract manufacturing organizations (CMOs) provide DPI with manufacturing, pharmacology, toxicology, regulatory, and clinical operations services to assist with drug development. Planning and execution of each individual drug development program includes identification of scientific areas best suited for utilization of CROs and CMOs to conduct some or all parts of a given drug development program.CONTRACTING OFFICE ADDRESSNational Center for Advancing Translational ScienceNINDS R&D Contracts Management Branch6001 Executive BlvdSuite 3287, MSC 9531Bethesda, MD 20892-9531**Use Rockville, MD 20852 for FedEx/USPS/Courier/Hand Delivery
N01TR-18-2006
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
10/13/17, 10:13 AM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
P00001
GENERATING POLYCLONAL ANTIBODIES AGAINST PTH-IA, PERIOD OF PERFORMANCE 9/29/20 - 9/28/2021, MODIFIED TO BIOTINYLATE EXCESS PRODUCT FOR FURTHER ANALYSIS.
Supplemental Agreement for work within scope
$2.8k
4/7/21
Not listed
GENERATING POLYCLONAL ANTIBODIES AGAINST PTH-IA, PERIOD OF PERFORMANCE 9/29/20 - 9/28/2021
Not listed
$24.2k
9/29/20